PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Eastern Biotech & Life Sciences FZ-LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Eastern Biotech & Life Sciences Introduces Comprehensive Cardiovascular Assessment in UAE - Eastern Biotech & Life Sciences, Dubai-based company established in Dubiotech Park introducing new Cardiovascular Assessment on the cutting edge of molecular medicine in Middle East Region
Eastern Biotech & Life Sciences Introduces Comprehensive Cardiovascular Assessment in UAE

 

NewswireToday - /newswire/ - Dubai, UAE, United Arab Emirates, 2007/08/29 - Eastern Biotech & Life Sciences, Dubai-based company established in Dubiotech Park introducing new Cardiovascular Assessment on the cutting edge of molecular medicine in Middle East Region.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Eastern Biotech & Life Sciences, Dubai based company established in Dubiotech Park introducing new Cardiovascular Assessment on the cutting edge of molecular medicine in Middle East Region. Based on the latest advancements in cardiovascular research, this groundbreaking assessment measures the most important CVD markers available, including crucial new independent factors, a diverse array of lipoproteins, and two computed ratios.

All of these advanced markers play a critical role in assessing the biochemical environment underlying cardiovascular health. This information allows the clinician to accurately address abnormalities relating to heart and vascular diseases.

According to Mr. Pankaj Sohaney-Manager, Middle East using this state-of-the-art assessment, you can now better identify individuals who don't show abnormalities in traditional markers of CVD-those who comprise almost 50 percent of all heart attack victims. A clear, color-coded test report will allow you to quickly interpret results, and design a unique, customized nutrition therapy program that can dramatically improve a patient's quality of life, and possibly even save it.

Perhaps the greatest tragedy is that the deleterious consequences of this deadly disease are very often preventable. With advances in medicine, researchers have discovered important early indicators that can significantly change the direction of prophylactic and therapeutic treatment, decreasing the incidence and halting the progression of the disease.

Testing is strongly recommended for patients with the following history or medical conditions:

• Family history of cardiovascular disease
• Personal history of myocardial infarction, peripheral artery disease, or coronary artery disease
• Obesity
• Diabetes
• Hypertension
• Thyroid disorders
• Stress
• Chronic illness (including chronic fatigue)
• Diets high in saturated and trans fats
• Sedentary lifestyle
• Use of alcohol, nicotine, drugs (including certain medications)
• Use of oral contraceptives
• Hormonal imbalances (estradiol, cortisol, insulin, melatonin)
• Post-menopause
• Renal disease.

The Comprehensive Cardiovascular Profile 2.0 incorporates the latest breakthroughs in cardiovascular disease research to provide advanced, early warning of CVD risk. This thorough evaluation features an advanced lipid profile with fractionation, independent risk markers (including homocysteine and hs-C-reactive protein), relative risk indices, and Metabolic Syndrome alerts. All of these advanced markers play a critical role in the biochemical environment underlying cardiovascular health. The insight they provide allows the clinician to accurately address abnormalities relating to heart and vascular diseases.

A clear, color-coded test report allows the clinician to quickly interpret results and design a novel, custom-tailored prevention program that can dramatically improve a patient's quality of life, and possibly even save it. The kit is developed by Genova Diagnostics and in Middle East it is available and promoted through Eastern Biotech Life Sciences FZ-LLC, anyone can get it by courier after calling or sending mail to info[.]easternbiotech.com

Eastern Biotech & Life Sciences (easternbiotech.com) based at DuBiotech, Dubai, is the first company in the Middle East to offer comprehensive genetic testing services. We have carefully examined the biotechnological horizon to identify the genetic tests most relevant to this region and offer them directly to the people of the Middle East.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Eastern Biotech & Life Sciences FZ-LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Eastern Biotech & Life Sciences Introduces Comprehensive Cardiovascular Assessment in UAE

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Pankaj Sohaney 
+97143692061 pankaj[.]easternbiotech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Eastern Biotech & Life Sciences FZ-LLC securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Eastern Biotech & Life Sciences FZ-LLC / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Inferior Vena Cava Filters Market to Register a Strong Growth by 2025 Notes Persistence Market Research
Plasma Component Separator Market Set to Surge Significantly During 2017-2025 Says PMR
Persistence Market Research Releases Fertility Enhancing Treatment Market Snapshot by 2017-2025
Disposable Diabetes Devices Market Expected to Generate Huge Profits by 2025 Finds Reports Persistence Market Research
Cardiac Biomarkers Market Expected to Generate Huge Profits by 2017-2025 Reports PMR
Stone Management System Market Foreseen to Grow Exponentially Over 2017-2025 Finds PMR
Global Hemoglobinopathy Market Worth US$ 788M by 2024 According to Persistence Market Research
Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail
Xenex Receives Top Honors from Frost & Sullivan for LightStrike™ - the Only Pulsed Xenon UV Disinfection System in the Healthcare Market
Partners HealthCare and GE Healthcare Launch 10-year Collaboration to Integrate Artificial Intelligence into Every Aspect of the Patient Journey
US Acute Care Solutions Celebrates 2-Year Anniversary
GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with Coronary CT Angiography
Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Persistence Market Research (P) Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)